Chardan Capital Reaffirms Buy Rating for Krystal Biotech (NASDAQ:KRYS)

Chardan Capital reiterated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a report issued on Wednesday morning,Benzinga reports. The firm currently has a $219.00 target price on the stock. Chardan Capital also issued estimates for Krystal Biotech’s FY2026 earnings at $8.80 EPS.

KRYS has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price on the stock. Finally, Citigroup lifted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and an average price target of $218.63.

Krystal Biotech Stock Down 3.6 %

NASDAQ KRYS opened at $132.23 on Wednesday. The company has a market capitalization of $3.82 billion, a price-to-earnings ratio of 44.22 and a beta of 0.79. Krystal Biotech has a twelve month low of $131.71 and a twelve month high of $219.34. The stock has a fifty day simple moving average of $171.56 and a 200 day simple moving average of $170.06.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Research analysts expect that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently added to or reduced their stakes in KRYS. Fifth Third Bancorp grew its holdings in shares of Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock valued at $31,000 after acquiring an additional 105 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Krystal Biotech in the third quarter worth $40,000. GF Fund Management CO. LTD. bought a new position in Krystal Biotech in the 4th quarter valued at $95,000. Covestor Ltd increased its position in shares of Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after purchasing an additional 642 shares during the last quarter. Finally, Avanza Fonder AB bought a new stake in shares of Krystal Biotech during the 4th quarter worth $119,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).